- Home
- TXMD vs HOTH Comparison
TXMD vs HOTH Comparison
Compare TXMD & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- HOTH
- Stock Information
- Founded
- TXMD 2008
- HOTH 2017
- Country
- TXMD United States
- HOTH United States
- Employees
- TXMD N/A
- HOTH N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- HOTH Health Care
- Exchange
- TXMD Nasdaq
- HOTH Nasdaq
- Market Cap
- TXMD 17.6M
- HOTH 18.0M
- IPO Year
- TXMD N/A
- HOTH 2019
- Fundamental
- Price
- TXMD $1.63
- HOTH $1.17
- Analyst Decision
- TXMD
- HOTH Strong Buy
- Analyst Count
- TXMD 0
- HOTH 2
- Target Price
- TXMD N/A
- HOTH $4.50
- AVG Volume (30 Days)
- TXMD 166.8K
- HOTH 316.9K
- Earning Date
- TXMD 11-12-2025
- HOTH 11-12-2025
- Dividend Yield
- TXMD N/A
- HOTH N/A
- EPS Growth
- TXMD N/A
- HOTH N/A
- EPS
- TXMD 0.03
- HOTH N/A
- Revenue
- TXMD $2,796,000.00
- HOTH N/A
- Revenue This Year
- TXMD $427.09
- HOTH N/A
- Revenue Next Year
- TXMD N/A
- HOTH N/A
- P/E Ratio
- TXMD $259.70
- HOTH N/A
- Revenue Growth
- TXMD 75.19
- HOTH N/A
- 52 Week Low
- TXMD $0.70
- HOTH $0.66
- 52 Week High
- TXMD $2.44
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- TXMD 55.64
- HOTH 41.23
- Support Level
- TXMD $1.55
- HOTH $1.14
- Resistance Level
- TXMD $2.08
- HOTH $1.22
- Average True Range (ATR)
- TXMD 0.28
- HOTH 0.08
- MACD
- TXMD 0.01
- HOTH -0.00
- Stochastic Oscillator
- TXMD 48.69
- HOTH 51.61
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).